{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:53:32Z","timestamp":1787496812014,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000064","name":"National Center of Complementary and Alternative Medicine","doi-asserted-by":"crossref","award":["1R01 AT002543-01A1"],"award-info":[{"award-number":["1R01 AT002543-01A1"]}],"id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000064","name":"National Center of Complementary and Alternative Medicine","doi-asserted-by":"crossref","award":["1R01AT006336-01A1"],"award-info":[{"award-number":["1R01AT006336-01A1"]}],"id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.atherosclerosis.2014.05.931","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T21:49:56Z","timestamp":1401832196000},"page":"449-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in\u00a0vitro and in\u00a0vivo through a SREBP2 dependent mechanism"],"prefix":"10.1016","volume":"235","author":[{"given":"Bin","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar Bahadur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2008-1040407","article-title":"Hepatic clearance of plasma low density lipoproteins","volume":"12","author":"Spady","year":"1996","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A\u00a0receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/01.CIR.97.15.1436","article-title":"Statin trials and goals of cholesterol-lowering therapy","volume":"97","author":"Grundy","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.coph.2005.10.012","article-title":"Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors","volume":"6","author":"Clark","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1194\/jlr.M500349-JLR200","article-title":"Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action","volume":"47","author":"Clark","year":"2006","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/VHRM.S29010","article-title":"Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib","volume":"8","author":"Miyares","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ahj.2011.11.017","article-title":"Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study","volume":"163","author":"Ballantyne","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1476-5381.2009.00460.x","article-title":"Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats","volume":"158","author":"Stroes","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2009.02.061","article-title":"Safety and tolerability of dalcetrapib","volume":"104","author":"Stein","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.271","article-title":"Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction","volume":"91","author":"Gutstein","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1208\/s12248-011-9254-0","article-title":"Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor","volume":"13","author":"Krishna","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib17","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib18","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib19","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"367","key":"10.1016\/j.atherosclerosis.2014.05.931_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"29","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ahj.2009.09.017","article-title":"Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome","volume":"158","author":"Schwartz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib24","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1194\/jlr.M016410","article-title":"Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters","volume":"52","author":"Castro-Perez","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib25","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1194\/jlr.M041541","article-title":"In\u00a0vivo effects of anacetrapib on prebeta HDL: improvement in HDL remodeling without effects on cholesterol absorption","volume":"54","author":"Wang","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/ATVBAHA.112.252932","article-title":"Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters","volume":"33","author":"Briand","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib27","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1194\/jlr.M008706","article-title":"Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport","volume":"51","author":"Niesor","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib28","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1194\/jlr.M036509","article-title":"Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-\/- mice","volume":"54","author":"Bell","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib30","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib31","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib33","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib34","first-page":"A11879","article-title":"Inhibitor K-312 with PCSK9 inhibitory property, exerts strong reduction of LDL-c and anti-atherosclerotic effects","volume":"126","author":"Shibata","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib35","first-page":"A13436","article-title":"A\u00a0novel CETP inhibitor, K-312, suppresses PCSK9 expression through the modulation of its promoter activity","volume":"126","author":"Miyosawa","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib36","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib37","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ceb.2007.02.004","article-title":"SREBP in signal transduction: cholesterol metabolism and beyond","volume":"19","author":"Bengoechea-Alonso","year":"2007","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib40","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib41","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1\u03b1 plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib42","first-page":"161","article-title":"Molecular dissection of human oncostatin M-mediated signal transductions through site-directed mutagenesis","volume":"23","author":"Liu","year":"2009","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib43","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/S0022-2275(20)37134-0","article-title":"Novel mechanism of transcriptional activation of hepatic LDL receptor by oncostatin M","volume":"38","author":"Liu","year":"1997","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib44","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1194\/jlr.M032599","article-title":"High-fructose diet downregulates long-chain acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR\/RXR signaling pathway","volume":"54","author":"Dong","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib45","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1345\/aph.1P446","article-title":"ANA and DAL: two novel cholesteryl ester transfer protein inhibitors","volume":"45","author":"Miyares","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib48","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1073\/pnas.96.20.11041","article-title":"A\u00a0proteolytic pathway that controls the cholesterol content of membranes, cells, and blood","volume":"96","author":"Brown","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2014.05.931_bib49","doi-asserted-by":"crossref","first-page":"27816","DOI":"10.1074\/jbc.M603781200","article-title":"Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands","volume":"281","author":"Yang","year":"2006","journal-title":"J\u00a0Biol Chem"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014011812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014011812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T17:31:30Z","timestamp":1649179890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014011812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0021915014011812"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.05.931","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in\u00a0vitro and in\u00a0vivo through a SREBP2 dependent mechanism","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.05.931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}